<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897949</url>
  </required_header>
  <id_info>
    <org_study_id>0462-022</org_study_id>
    <secondary_id>2009_589</secondary_id>
    <nct_id>NCT00897949</nct_id>
  </id_info>
  <brief_title>MK0462 in Treatment of Migraine With Recurrence (MK0462-022)</brief_title>
  <official_title>A Randomized, Triple-Blind, Double-Dummy, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety and Efficacy of MK0462 10 mg p.o. and MK0462 5 mg p.o. for the Treatment of Acute Migraine and Migraine Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine
      attack and treatment of up to two headache recurrences compared to placebo.

      The long term extension study which pools patients from MK0462-022, -025, and -029 is
      described in NCT01286207.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 1995</start_date>
  <completion_date type="Actual">July 1996</completion_date>
  <primary_completion_date type="Actual">January 1996</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Relief at 2 Hours After the Initial Dose of Test Drug</measure>
    <time_frame>2 hours after initial dose of test drug</time_frame>
    <description>Patients reporting pain relief (defined as a reduction of headache severity from grades 2/3 at baseline to 0/1) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Free at 2 Hours After the Initial Dose of Test Drug</measure>
    <time_frame>2 hours after initial dose of test drug</time_frame>
    <description>Patients reporting pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No Disability at 2 Hours After the Initial Dose of Test Drug</measure>
    <time_frame>2 hours after initial dose of test drug</time_frame>
    <description>Patients with no disability at 2 hours after the initial dose of test drug. Functional disability was subjectively rated on a scale from grade 0 to 3: Grade 0 - Normal, Grade 1 - Daily activities mildly impaired, Grade 2 - Daily activities severely impaired, Grade 3 - Unable to carry out daily activities, requires bedrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Escape Medication at 2 Hours After the Initial Dose of Test Drug</measure>
    <time_frame>2 hours after initial dose of test drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief 2 Hours After Treatment for Headache Recurrence</measure>
    <time_frame>2 hours after treatment for recurrence</time_frame>
    <description>Patients reporting pain relief 2 hours after treatment for headache recurrence (defined as the return of headache to grade 2 or 3 within 24 hours of the initial dose in patients who reported pain relief (grades 0 or 1) at 2 hours).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1473</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>Rizatriptan 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rizatriptan 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rizatriptan benzoate (MK0462)</intervention_name>
    <description>Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.</description>
    <arm_group_label>Rizatriptan 10 mg</arm_group_label>
    <arm_group_label>Rizatriptan 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: placebo</intervention_name>
    <description>Placebo to rizatriptan</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient had at least a 6-month history of migraine, with or without aura

          -  Patient was male, or if female must have been postmenopausal, surgically sterilized,
             or taking adequate contraceptive precautions

          -  Patient was judged to be in good health, apart from migraine

        Exclusion Criteria:

          -  Patient was pregnant or a nursing mother

          -  Patient had abused drugs or alcohol within 12 months prior to entering the study

          -  Patient had a history of cardiovascular disease

          -  Patient had clinically significant ECG abnormality

          -  Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic
             of less than 95 mm Hg at screening

          -  Patient received treatment with an investigational device or compound within 30 days
             of the study start

          -  Patient typically suffered from less then 1 or more than 8 attacks of migraine per
             month

          -  Patient had difficulty in distinguishing his/her migraine attacks from tension or
             interval headaches

          -  Patient had prior exposure to rizatriptan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <reference>
    <citation>Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009 Mar;49(3):395-403. doi: 10.1111/j.1526-4610.2009.01346.x. Epub 2008 Feb 12.</citation>
    <PMID>19222588</PMID>
  </reference>
  <reference>
    <citation>Ho TW, Fan X, Rodgers A, Lines CR, Winner P, Shapiro RE. Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults. Cephalalgia. 2009 Jul;29(7):711-8. doi: 10.1111/j.1468-2982.2008.01788.x. Epub 2009 Feb 3.</citation>
    <PMID>19210513</PMID>
  </reference>
  <results_reference>
    <citation>Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B, Jiang K, Reines S, Block G. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache. 1998 Apr;38(4):281-7.</citation>
    <PMID>9595867</PMID>
  </results_reference>
  <results_reference>
    <citation>Block GA, Goldstein J, Polis A, Reines SA, Smith ME. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups. Headache. 1998 Nov-Dec;38(10):764-71.</citation>
    <PMID>11284464</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <results_first_submitted>September 26, 2009</results_first_submitted>
  <results_first_submitted_qc>April 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2011</results_first_posted>
  <last_update_submitted>February 13, 2015</last_update_submitted>
  <last_update_submitted_qc>February 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rizatriptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at 28 sites in the United States and 18 in 9 other countries.
First Patient Treated: Mar 1995
Last Patient Treated: Jan 1996.</recruitment_details>
      <pre_assignment_details>Outpatients randomized at the prestudy visit were given study drug and administration instructions. If patients had not treated an attack within 2 months of being enrolled, they were required to return for a rescreen visit. If by 4 months after being enrolled patients still had not treated an attack, they were discontinued from the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rizatriptan 5 mg</title>
          <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="P2">
          <title>Rizatriptan 10 mg</title>
          <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo matching Rizatiptan 5 mg and Rizatriptan 10 mg orally once for treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="554">Patients who were allocated study drug</participants>
                <participants group_id="P2" count="549">Patients who were allocated study drug</participants>
                <participants group_id="P3" count="370">Patients who were allocated study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients Treated</title>
              <participants_list>
                <participants group_id="P1" count="458">Patients who took study drug</participants>
                <participants group_id="P2" count="456">Patients who took study drug</participants>
                <participants group_id="P3" count="304">Patients who took study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="450">Patients who took study drug and completed the study</participants>
                <participants group_id="P2" count="446">Patients who took study drug and completed the study</participants>
                <participants group_id="P3" count="301">Patients who took study drug and completed the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Uncoorperative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Prestudy Labs</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Baseline ECG</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Need for Concom. Med.</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Migraine Attack</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not take study drug</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rizatriptan 5 mg</title>
          <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="B2">
          <title>Rizatriptan 10 mg</title>
          <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo matching Rizatiptan 5 mg and Rizatriptan 10 mg orally once for treatment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="458"/>
            <count group_id="B2" value="456"/>
            <count group_id="B3" value="304"/>
            <count group_id="B4" value="1218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" spread="9.6"/>
                    <measurement group_id="B2" value="40.7" spread="9.6"/>
                    <measurement group_id="B3" value="40.6" spread="10.5"/>
                    <measurement group_id="B4" value="40.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="394"/>
                    <measurement group_id="B2" value="402"/>
                    <measurement group_id="B3" value="259"/>
                    <measurement group_id="B4" value="1055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="430"/>
                    <measurement group_id="B2" value="422"/>
                    <measurement group_id="B3" value="286"/>
                    <measurement group_id="B4" value="1138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexican-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Syrian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anglo-Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Headache Severity</title>
          <description>Each patient rated headache severity on a 4-grade scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain)</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grade 0, 1: No pain, Mild, or missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="202"/>
                    <measurement group_id="B4" value="816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Relief at 2 Hours After the Initial Dose of Test Drug</title>
        <description>Patients reporting pain relief (defined as a reduction of headache severity from grades 2/3 at baseline to 0/1) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain.</description>
        <time_frame>2 hours after initial dose of test drug</time_frame>
        <population>The primary analysis employed an “all-patients-treated” approach that included all patients who had at least one record of pain severity within 2 hours after the initial dose. Missing data were replaced by carrying forward the preceding value.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Rizatiptan 5 mg and Rizatriptan 10 mg orally once for treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief at 2 Hours After the Initial Dose of Test Drug</title>
          <description>Patients reporting pain relief (defined as a reduction of headache severity from grades 2/3 at baseline to 0/1) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain.</description>
          <population>The primary analysis employed an “all-patients-treated” approach that included all patients who had at least one record of pain severity within 2 hours after the initial dose. Missing data were replaced by carrying forward the preceding value.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="457"/>
                <count group_id="O2" value="455"/>
                <count group_id="O3" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reporting pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285"/>
                    <measurement group_id="O2" value="322"/>
                    <measurement group_id="O3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not reporting pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Free at 2 Hours After the Initial Dose of Test Drug</title>
        <description>Patients reporting pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain.</description>
        <time_frame>2 hours after initial dose of test drug</time_frame>
        <population>An “all-patients-treated” approach was employed that included all patients who had at least one record of pain severity within 2 hours after the initial dose. Missing data were replaced by carrying forward the preceding value.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Rizatiptan 5 mg and Rizatriptan 10 mg orally once for treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Free at 2 Hours After the Initial Dose of Test Drug</title>
          <description>Patients reporting pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain.</description>
          <population>An “all-patients-treated” approach was employed that included all patients who had at least one record of pain severity within 2 hours after the initial dose. Missing data were replaced by carrying forward the preceding value.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="457"/>
                <count group_id="O2" value="455"/>
                <count group_id="O3" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reporting no pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reporting pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307"/>
                    <measurement group_id="O2" value="262"/>
                    <measurement group_id="O3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>No Disability at 2 Hours After the Initial Dose of Test Drug</title>
        <description>Patients with no disability at 2 hours after the initial dose of test drug. Functional disability was subjectively rated on a scale from grade 0 to 3: Grade 0 – Normal, Grade 1 - Daily activities mildly impaired, Grade 2 - Daily activities severely impaired, Grade 3 - Unable to carry out daily activities, requires bedrest</description>
        <time_frame>2 hours after initial dose of test drug</time_frame>
        <population>An “all-patients-treated” approach was employed that included all patients who had at least one record of functional disability within 2 hours after the initial dose. Missing data were replaced by carrying forward the preceding value.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Rizatiptan 5 mg and Rizatriptan 10 mg orally once for treatment</description>
          </group>
        </group_list>
        <measure>
          <title>No Disability at 2 Hours After the Initial Dose of Test Drug</title>
          <description>Patients with no disability at 2 hours after the initial dose of test drug. Functional disability was subjectively rated on a scale from grade 0 to 3: Grade 0 – Normal, Grade 1 - Daily activities mildly impaired, Grade 2 - Daily activities severely impaired, Grade 3 - Unable to carry out daily activities, requires bedrest</description>
          <population>An “all-patients-treated” approach was employed that included all patients who had at least one record of functional disability within 2 hours after the initial dose. Missing data were replaced by carrying forward the preceding value.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="457"/>
                <count group_id="O2" value="454"/>
                <count group_id="O3" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="209"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mildly Impaired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severely Impaired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Requires Bedrest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Escape Medication at 2 Hours After the Initial Dose of Test Drug</title>
        <time_frame>2 hours after initial dose of test drug</time_frame>
        <population>An “all-patients-treated” approach was employed that included all patients who had at least one record of pain severity within 2 hours after the initial dose. Missing data were replaced by carrying forward the preceding value.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Rizatiptan 5 mg and Rizatriptan 10 mg orally once for treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Escape Medication at 2 Hours After the Initial Dose of Test Drug</title>
          <population>An “all-patients-treated” approach was employed that included all patients who had at least one record of pain severity within 2 hours after the initial dose. Missing data were replaced by carrying forward the preceding value.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="458"/>
                <count group_id="O2" value="456"/>
                <count group_id="O3" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Used escape medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not use escape medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357"/>
                    <measurement group_id="O2" value="380"/>
                    <measurement group_id="O3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief 2 Hours After Treatment for Headache Recurrence</title>
        <description>Patients reporting pain relief 2 hours after treatment for headache recurrence (defined as the return of headache to grade 2 or 3 within 24 hours of the initial dose in patients who reported pain relief (grades 0 or 1) at 2 hours).</description>
        <time_frame>2 hours after treatment for recurrence</time_frame>
        <population>Patients with initial headache recurrence who took rizatriptan 5 mg or 10 mg were prerandomized (ratio=1:1) to either rizatriptan 5 mg or 10 mg, respectively, or to placebo (ratio=1:1); and who took placebo, to either 5 mg or 10 mg of rizatriptan (ratio=1:1). Only those who took rizatriptan for their initial headache were considered for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rizatriptan 5 mg / Rizatriptan 5 mg</title>
            <description>Rizatriptan 5 mg initially, prerandomized to rizatriptan 5 mg</description>
          </group>
          <group group_id="O2">
            <title>Rizatriptan 5 mg / Placebo</title>
            <description>Rizatriptan 5 mg initially, prerandomized to placebo</description>
          </group>
          <group group_id="O3">
            <title>Rizatriptan 10 mg / Rizatriptan 10 mg</title>
            <description>Rizatriptan 10 mg initially, prerandomized to rizatriptan 10 mg</description>
          </group>
          <group group_id="O4">
            <title>Rizatriptan 10 mg / Placebo</title>
            <description>Rizatriptan 10 mg initially, prerandomized to placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo / Rizatriptan 5 mg</title>
            <description>Placebo initially, prerandomized to rizatriptan 5 mg</description>
          </group>
          <group group_id="O6">
            <title>Placebo / Rizatriptan 10 mg</title>
            <description>Placebo initially, prerandomized to rizatriptan 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief 2 Hours After Treatment for Headache Recurrence</title>
          <description>Patients reporting pain relief 2 hours after treatment for headache recurrence (defined as the return of headache to grade 2 or 3 within 24 hours of the initial dose in patients who reported pain relief (grades 0 or 1) at 2 hours).</description>
          <population>Patients with initial headache recurrence who took rizatriptan 5 mg or 10 mg were prerandomized (ratio=1:1) to either rizatriptan 5 mg or 10 mg, respectively, or to placebo (ratio=1:1); and who took placebo, to either 5 mg or 10 mg of rizatriptan (ratio=1:1). Only those who took rizatriptan for their initial headache were considered for analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the 24 hours treatment period, and up to and including 7 days after the last dose of study therapy.</time_frame>
      <desc>Although a patient may have had two or more adverse experiences the patient is counted only once in a category. The same patient may appear in different categories.
The subjects reported at risk are subjects with follow-up after at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rizatriptan 5 mg</title>
          <description>Rizatriptan 5 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="E2">
          <title>Rizatriptan 10 mg</title>
          <description>Rizatriptan 10 mg orally once for treatment of single migraine attack</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo matching Rizatiptan 5 mg and Rizatriptan 10 mg orally once for treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CRISP Dictionary</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CRISP Dictionary</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="254" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia/Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pain, Abdominal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pain, Chest</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Respiratory, Upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Amino Transferase (ALT) Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Aspartate Amino Transferase (AST) Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tightness, Regional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Hypesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort, Pharyngeal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="456"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pooled Extension data for PN022- NCT00897949; PN025- NCT00899379 and PN029- NCT00897104 appears in NCT01286207</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President,Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

